Biocept has announced the commercial availability of its liquid biopsy test for progesterone receptor (PR), which can be used for the detection and monitoring of a key biomarker in the blood of patients with breast cancer. The company noted that the ability to detect PR expression in circulating tumor cells complements its existing ER and HER2 assays for biomarker analysis in breast cancer. Biocept's Target Selector PR expression test is performed on circulating tumor cells using fluorescently labeled antibodies. The company's liquid biopsy tests are performed in its CLIA-certified, CAP-accredited laboratory in San Diego.
Norgen Biotek, based in Ontario, has launched a Small RNA Library Prep Kit for Illumina sequencing instruments as well as sequencing services on Illumina instruments. The Small RNA Library Prep Kit needs between 0.5 nanograms and 1 nanogram of input RNA and can process samples from plasma, serum, blood, cerebral spinal fluid, urine, and exosomes, according to the company. Turnaround time is less than five hours. Norgen also offers complementary products, including NGS-compatible cel-miR-39 spike-in and an NGS library quantification kit. The services Norgen launched include isolation, library prep, sequencing, and bioinformatics. Sequencing can be performed on Illumina's MiSeq or NextSeq 500 instruments and includes small RNA-seq, RNA-seq, 16S metagenomics, targeted DNA or RNA sequencing, exome sequencing, and whole-genome sequencing.
Exact Diagnostics launched its verification panels for IVD use. The panels include adenovirus; BKV; CMV; EBV; HBV; HCV; HHV-6A; HHV-6B; HIV-1; HSV-1; HSV-2; VZV; and Zika. They can be used to establish reference points to measure various analytes in molecular assays, the firm said.
For more new products and services, please visit the New Products page on our website.